---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-083558"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2022-12-29T23:59:59+00:00"
generated_at: "2026-06-20T21:55:13.969252+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Virpax receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure

## Summary
- Received Nasdaq notice on Dec 22, 2022 for non-compliance with minimum $1.00 bid price rule.
- Closing bid price below $1.00 for last 30 consecutive business days triggered the notice.
- Compliance deadline is June 20, 2023; must close at $1.00+ for 10 consecutive days.
- Eligible for additional 180-day cure period if meeting other listing requirements and pursuing reverse split.
- Company is evaluating options to regain compliance; no immediate delisting.

## SEC filing metadata
- accession: 0001213900-22-083558
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2022-12-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390022083558/0001213900-22-083558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390022083558/ea170895-8k_virpax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-083558
- JSON: https://secwatch.observer/filing/0001213900-22-083558.json
- Plain text: https://secwatch.observer/filing/0001213900-22-083558.txt

## Key facts
- Listing & Compliance Notices
  Virpax Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: December 22, 2022, Virpax Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid p
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390022083558/0001213900-22-083558-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.